|Bid||8.66 x 800|
|Ask||8.71 x 3100|
|Day's Range||8.29 - 8.93|
|52 Week Range||4.96 - 9.23|
|Beta (5Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.86|
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that on April 12, 2021, the compensation committee of the Company's Board of Directors granted a non-qualified stock option award to purchase 125,622 shares of its common stock and a restricted stock unit award for 26,315 shares in connection with the commencement of employment of its new Chief People Officer, Sarah O'Brien, under the Company's 2016 Employment Commencement Incentive Plan (the "Inducement Plan"). The stock options and restricted stock units were granted as an inducement material to Ms. O'Brien becoming an employee of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
The company's Japanese partner initiated pivotal late-stage studies of Ardelyx's lead candidate.